Galectin治疗 GALT 深 沪
等待开盘 04-02 09:30:00 美东时间
2.78
-0.010
-0.36%
华盛通- 最 高2.92
- 今 开2.78
- 成交量 21.12万股
- 最 低 2.765
- 昨 收 2.79
- 总市值 1.79亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 1.21
- 委 比 38.08%
- 总股本 6447.28万
- 历史最高 19.11
- 量 比 2.00
- 振 幅 5.56%
- 历史最低 0.49
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share
03-31 22:19
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported that its belapectin program, targeting galectin-3, showed progress in reducing varices and positive biomarker data in patients with MASH cirrhosis. The company secured an additional $10 million line of credit, bolstered its board with Dr. Henry Brem, and saw improved financial stability with reduced R&D expenses, narrowing its net loss.
03-31 12:00
Galectin Therapeutics appoints Henry Brem to board as independent director
Galectin Therapeutics appoints Henry Brem to board as independent director Galectin Therapeutics appointed Henry Brem as an independent director to its board. Brem is the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurg
03-17 19:51
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Galectin Therapeutics Inc. appointed Henry Brem, M.D., as an independent director. Dr. Brem is a leading neurosurgeon-scientist with extensive experience in translational medicine, having developed image-guided surgical techniques and localized drug delivery systems. His expertise will support Galectin’s development of belapectin for patients with MASH cirrhosis and portal hypertension. The company continues to strengthen its board with scientifi...
03-17 12:00
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
argenx reported strong FY2025 financial results with $1.3B Q4 and $4.2B global product net sales, representing 90% YoY growth, and delivered $1.1B in operating income, marking its first year of operating profitability. Key highlights include VYVGART's label expansion, a PDUFA target date of May 10, 2026 for anti-AChR Ab-negative gMG, and strategic priorities to advance Vision 2030. argenx is expanding its impact in autoimmune diseases, advancing ...
02-26 06:00
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clini...
02-22 18:42
Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc
Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc Kary Eldred, a director of Galectin Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technolo
02-10 05:25
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt wil
01-22 06:01
Galectin Advances Belapectin Program, Secures New Insider Financing
Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, G...
2025-12-19 21:14
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
